1. Home
  2. OCSL vs SLDB Comparison

OCSL vs SLDB Comparison

Compare OCSL & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oaktree Specialty Lending Corporation

OCSL

Oaktree Specialty Lending Corporation

N/A

Current Price

$13.15

Market Cap

1.1B

Sector

Finance

ML Signal

N/A

Logo Solid Biosciences Inc.

SLDB

Solid Biosciences Inc.

N/A

Current Price

$9.89

Market Cap

1.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OCSL
SLDB
Founded
2007
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.1B
IPO Year
2007
2017

Fundamental Metrics

Financial Performance
Metric
OCSL
SLDB
Price
$13.15
$9.89
Analyst Decision
Hold
Strong Buy
Analyst Count
4
11
Target Price
$12.63
$16.36
AVG Volume (30 Days)
560.2K
876.6K
Earning Date
05-05-2026
05-12-2026
Dividend Yield
12.73%
N/A
EPS Growth
N/A
34.97
EPS
0.20
N/A
Revenue
N/A
$8,094,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$0.31
N/A
P/E Ratio
$65.80
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.63
$3.79
52 Week High
$14.31
$11.45

Technical Indicators

Market Signals
Indicator
OCSL
SLDB
Relative Strength Index (RSI) 63.61 56.51
Support Level $12.31 $5.21
Resistance Level $13.39 $11.45
Average True Range (ATR) 0.27 0.43
MACD 0.03 0.06
Stochastic Oscillator 90.64 67.25

Price Performance

Historical Comparison
OCSL
SLDB

About OCSL Oaktree Specialty Lending Corporation

Oaktree Specialty Lending Corp is a specialty finance company. The company provides lending services and invests in small and mid-sized companies. The company's investment objective is to maximize its portfolio's total return by generating current income from debt investments, and to a lesser extent, capital appreciation from equity investments. The company provides customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets. The company operates as a single reportable segment and derives revenues from investing in originated loans and other securities, including broadly syndicated loans, of U.S. private companies and manages the business on a consolidated basis.

About SLDB Solid Biosciences Inc.

Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.

Share on Social Networks: